AB0389 the Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses
doi 10.1136/annrheumdis-2017-eular.4401
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2017
Authors
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism